CTRI/2018/10/015958Not yet recruitingPhase 3
Docetaxel or Cisplatin radiosensitizer in Head and Neck cancer patients for curative or adjuvant chemoradiation
Trial Snapshot
- Phase
- Phase 3
- Status
- Not yet recruiting
- Sponsor
- Tata Memorial Centre
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •1.Participants must have a histologically confirmed stage III-IV squamous cell cancers of the head and neck region ( AJCC-UICC staging ,8th edition).
- •2.Participants must warrant CTRT must warrant at least one of the following
- •a.Radical setting : Stage III-IV head and neck cancer
- •b.Adjuvant setting : Stage III-IV head and neck cancer postoperative with one of the below mentioned feature on pathology specimen
- •i.Extracapsular extension
- •ii.Margin positive
- •iii.Close margin ( cut margin 0.5 mm or below)
- •3.Participants must have malignancy arising from one of the following sites oral cavity, pharynx ( inclusive of oropharynx, hypopharynx) or larynx ( inclusive of supraglottis, glottis and subglottis) or CUP ( carcinoma unknown primary) with neck nodes
- •4.ECOG performance status <=2
- •5.Participants must have normal organ and marrow function as defined below:
- •a.Leukocytes>=3,000/mcL
- •b.Platelets>=100,000/mcL
- •c.Total bilirubin < 1.5 Ã? institutional upper limit of normal
- •d.AST(SGOT)/ALT(SGPT) <=1.5 Ã? institutional upper limit of normal
- •e.Calculated Creatinine clearance > 50 ml/min
Exclusion Criteria
- •1.Participants who are receiving any other investigational agents.
- •2.Primary sites of malignancy major salivary gland or nasopharynx or skin
- •3.Patients with QTc prolongation defined as QTc interval greater than 480 ms in view of risk of sudden cardiac death associated with use of antiemetics.
- •4.History of allergic reactions attributed to compounds of similar chemical or biologic composition to any agents used in study.
- •5.Uncontrolled intercurrent illness including, but not limited to tuberculosis, diabetes, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, renal failure (on dialysis), active gastrointestinal bleeding, cerebrovascular accidents, inflammatory bowel disease, known hyperkalemia ( CTCAE version 4.02 grade 3 or above which is persistent over 1 week) or psychiatric illness/social situations that would limit compliance with study requirements.
- •6.Presence of grade 3 or above sensory hearing loss
- •7.Pregnant women and breastfeeding women are excluded from this study because docetaxel has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants. These potential risks may also apply to other agents used in this study.
- •8.HIV-positive, Active Hepatitis B and Active Hepatitis C seropositive patients are excluded from this study.
Investigators
Similar Trials
Not yet recruiting
Phase 2
Docetaxel chemotherapy with radiation in head and neck cancerCTRI/2017/05/008700Tata Memorial Hospital600
Not yet recruiting
Phase 3
Study of different type of chemotherapy in Head and Neck Cancer PatientsCTRI/2024/06/068752Tata Memorial Hospital
Recruiting
Phase 2
DCF-RT for T4b ECLocally advanced esophageal cancerEsophageal cancerJPRN-jRCTs051190058Miyata Hiroshi20
Completed
Phase 2
Docetaxel in combination with either cisplatin (DC) or gemcitabine (DG) in unresectable non-small sell lung carcinoma (NSCLC)on-small sell lung carcinoma (NSCLC)JPRN-C000000310The Tokyo cooperative oncology group150
Completed
Phase 1
Paclitaxel plus cisplatin and concurrent radiation for unresectable, locally recurrent or remnant gastric cancer in the left upper abdomen – phase I studyunresectable, locally recurrent or remnant gastric cancerJPRN-C000000246Multi-modality therapy for gastric cancer study group6